Moderna announced Thursday that it anticipates selling at least $19 Billion of Covid-19 vaccine in the year ahead, following fourth quarter earnings reports that exceeded analysts’ revenue and earnings estimates.

Based on Refinitiv’s average analyst estimates, here’s what the company did compared with Wall Street’s expectations.

• Adjusted EPS: $11.29 vs. $9.90 Expected
• Revenue: Expected $6.78 billion, $7.2 Billion

Moderna earned $4.9 billion net income in the fourth quarter. Moderna reported a revenue of $18.5billion in 2021, and distributed 807,000,000 vaccine doses globally.

Moderna has only one commercially available vaccine: Covid. Spikevax was approved for adult use by both the Food and Drug Administration and Centers for Disease Control and Prevention in the past month.

Moderna has begun a clinical study for a booster shot specifically targeting the Omicron Covid type. It’s not clear if there will be strong interest in an omicron booster. infections from the variant drop sharply in the U.S.Other parts of the globe.

CNBC’s Stephane Bancel, CEO of the company, said last week that although it appears to be over, the pandemic could still be in its final stages. However, he stated that people 50 years and older will require a boost once per year for those who have underlying conditions.

“There’s an 80% chance that as omicron evolves or SarsCov-2 virus evolves, we are going to see less and less virulent viruses,” Bancel told “Squawk Box Asia.” He said that there is a 20% chance of a new mutation becoming more dangerous than the omicron.

Moderna’s vaccine eligibility age has not been lowered by the FDA to adults..Moderna applied to the FDA for approval last summer of its vaccine to teenagers aged 12–17. Moderna has asked the FDA to review data about the risk of myocarditis. This is a rare form of heart inflammation.

Moderna stated that it won’t ask the FDA for an increase in eligibility to 6-11-year-olds, until the FDA authorizes shots for teens. It expects to publish clinical trial data for its vaccine in the March.

More than 207 million Moderna vaccine doses were administered in the U.S. since December 2020 when Moderna was approved by FDA on an emergency basis.